Graduate School of Economics and International Relations

Paul Zink Appointed to the Board of American Rare Earths

Retrieved on: 
Monday, August 21, 2023
EMX, Society, Corporate development, Business, ASX, Lehigh University, Koch Industries, Strategic planning, Metallurgy, Colorado School of Mines, Sarly Adre Sarkum, Graduate School of Economics and International Relations, Acquisition, ARR, Capital, J. P. Morgan, Research, Financial management, Audit committee, BA, Lithium, Rare-earth element, Management, Mining, Economics

DENVER, Aug. 21, 2023 (GLOBE NEWSWIRE) -- American Rare Earths (ASX: ARR | ADRs - OTCQX: AMRRY | Common Shares - OTCQB: ARRNF | FSE:1BHA) (ARR or the Company) is pleased to announce that Mr. Paul Zink has joined the Board of the Company.

Key Points: 
  • DENVER, Aug. 21, 2023 (GLOBE NEWSWIRE) -- American Rare Earths (ASX: ARR | ADRs - OTCQX: AMRRY | Common Shares - OTCQB: ARRNF | FSE:1BHA) (ARR or the Company) is pleased to announce that Mr. Paul Zink has joined the Board of the Company.
  • “We are very pleased to add Paul to our board as we build our US base,” says Creagh O’Connor, Chairman, American Rare Earths.
  • “I am excited to join American Rare Earths as it transitions its management focus to the United States.
  • This announcement has been authorized for release by the Board of American Rare Earths.

Gamida Cell Appoints Terry Coelho as CFO

Retrieved on: 
Monday, May 22, 2023
Biotechnology, Pharmaceutical, Health, Stem Cells, Bachelor, Therapy, American University School of International Service, Diversey, Mars, DC, First wave, Sealed Air, MBA, Cell, AstraZeneca, Graduate School of Economics and International Relations, Novartis, Boxed warning, Mars, Incorporated, Atmosphere of Earth, Patient, IBMEC, CFO, Collection, Bone marrow, Regulation of tobacco by the U.S. Food and Drug Administration, Hematopoietic stem cell transplantation, Food, Pharmaceutical industry, Management, Economics

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the appointment of Terry Coelho as Chief Financial Officer effective immediately.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the appointment of Terry Coelho as Chief Financial Officer effective immediately.
  • Shai Lankry, who has served as the company’s CFO for the past five years, is stepping down as CFO today and will leave the company June 2.
  • “Terry has tremendous experience as CFO of commercial-stage biopharmaceutical companies.
  • “Omisirge has great commercial potential and the opportunity to fill a critical need for patients in need of stem cell transplant,” said Ms. Coelho.

Doug McNitt Joins Calix Leadership Team, Bringing Deep Expertise and Experience Leading Legal Teams across Artificial Intelligence, Cloud and Cybersecurity Industries

Retrieved on: 
Tuesday, May 3, 2022
Data Management, Security, Technology, Software, Networks, Internet, Online, Privacy, Forward-looking statement, Calix Inc., Form 10-Q, University, Automation, Digital divide, Cisco Systems, NYSE, Sourcefire, AOL, Annual report, Industry, Artificial intelligence, Ethics, WebMethods, Government, Graduate School of Economics and International Relations, International relations, SEC, Solution, Growth, Stanford University, Acquisition, Risk management, Management, Economics, Calix

(NYSE: CALX) today announced that Doug McNitt, a legal expert with deep experience leading teams across the artificial intelligence, cloud, and cybersecurity Industries, has joined the company as executive vice president and general counsel, effective today.

Key Points: 
  • (NYSE: CALX) today announced that Doug McNitt, a legal expert with deep experience leading teams across the artificial intelligence, cloud, and cybersecurity Industries, has joined the company as executive vice president and general counsel, effective today.
  • Doug is responsible for driving the legal strategy and operations and developing the future generation of legal talent at Calix.
  • With its industry leading quarterly cadence model for product introduction, Calix is expanding its cloud portfolio at a rapid pace.
  • Doug is a perfect fit for Calix based on his deep expertise in the markets, sectors and customers who are adopting our All-platform solutions.

E2open Names Marje Armstrong as New Chief Financial Officer

Retrieved on: 
Wednesday, April 27, 2022
Software, Networks, Internet, Technology, Supply Chain Management, Logistics, Supply Chain Management, Transport, Retail, Treasury, E2open, Armstrong, LLC, Trustee, Leg, Leadership, Wall Street, Stanford University, Education, Machine learning, CFO, International relations, Artificial intelligence, Goldman Sachs, Dropbox (service), The Baldwin School, Growth, Graduate School of Economics and International Relations, Morgan Stanley, NYSE, Retirement, Dropbox, FP, Software as a service, 3D printing, Security (finance), Economics

E2open Parent Holdings, Inc. (NYSE: ETWO), a leading network-based provider of a cloud-based, mission-critical, end-to-end supply chain management platform, announces the appointment of Marje Armstrong as chief financial officer, effective May 16, 2022.

Key Points: 
  • E2open Parent Holdings, Inc. (NYSE: ETWO), a leading network-based provider of a cloud-based, mission-critical, end-to-end supply chain management platform, announces the appointment of Marje Armstrong as chief financial officer, effective May 16, 2022.
  • Were thrilled to welcome Marje to our leadership team as E2opens next CFO, said Michael Farlekas, chief executive officer of E2open.
  • Armstrong starts with E2open on May 16, and Janik will stay with the company to transition through the next quarterly earnings cycle.
  • E2open and the E2open logo are registered trademarks of E2open, LLC.

Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer

Retrieved on: 
Tuesday, January 4, 2022
Growth, Facioscapulohumeral muscular dystrophy, Private Securities Litigation Reform Act, Gene expression, Population, Wesleyan University, U.S. Securities and Exchange Commission, Bank of America, MBA, FDA, Lists of diseases, Thalassemia, Bank, Wharton School of the University of Pennsylvania, Losmapimod, Deutsche Bank, Graduate School of Economics and International Relations, GLOBE, Company, Fulcrum, Sickle cell disease, Fetal hemoglobin, Oppenheimer, Therapy, FSHD, Research, International relations, University, Patient, Wendell Pritchett, Nasdaq, Accounting, Security (finance), Biotechnology, UBS, Pharmaceutical industry, Economics

CAMBRIDGE,Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Esther Rajavelu as Chief Financial Officer.

Key Points: 
  • CAMBRIDGE,Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Esther Rajavelu as Chief Financial Officer.
  • Ms. Rajavelu brings nearly 20 years of experience in the life sciences sector spanning equities research, investment banking and strategic consulting.
  • She will be responsible for overseeing Fulcrums financial operations, including financial planning, reporting, accounting, and investor relations.
  • I am incredibly excited to be joining Fulcrum at this pivotal time, said Ms. Rajavelu.

BioHarvest Sciences Inc. Announces Appointment of David Tsur to Board of Directors

Retrieved on: 
Thursday, October 21, 2021
Ministry of Industry and Trade (Vietnam), Hebrew University of Jerusalem, Eleazar Sukenik, Fruit, USD, Technology, FSE, Canadian Securities Exchange, BHSC, CAD, Board of directors, CSE, Patient, NASDAQ, CBD, Ministry, Business administration, Graduate School of Economics and International Relations, Company, Board, CEO, Tel Aviv Stock Exchange, London, Plant, International relations, Commercial, Business, Cannabis, London Stock Exchange, Rehovot, Seaweed, Management

To view an enhanced version of this graphic, please visit:

Key Points: 
  • To view an enhanced version of this graphic, please visit:
    "We are excited to welcome David to Bioharvest's board," said Dr. Zaki Rakib, Chairman of the Board.
  • David Tsur said: "I am very excited to join the Board of BioHarvest.
  • Ilan Sobel, CEO of BioHarvest, commented: "David is an important addition to the Board as we look to deliver against the Company's strategic objectives.
  • Most importantly, David joining the Board is a testament to our ability to attract highly qualified individuals to join our team.

AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

Retrieved on: 
Monday, August 16, 2021
NASDAQ, MBA, Graduate School of Economics and International Relations, U.S. Securities and Exchange Commission, Arbutus Biopharma, Novartis, Committee, Niclosamide, DC, Mars, Clinical trial, CEO, Achievement, IBMEC, Company, American University School of International Service, Bachelor, COVID-19, International Service for the Acquisition of Agri-biotech Applications, GLOBE, EPI, Exocrine pancreatic insufficiency, Nature, Security (finance), Patient, Board, Growth, Sealed Air, Executive, Board of directors, BCPC, Knowledge, Diarrhea, Cystic fibrosis, BOCA, International relations, Management, Pharmaceutical industry

BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AzurRx or the Company) ( NASDAQ: AZRX ), a company specializing in the development of targeted non-systemic, therapies forgastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately.

Key Points: 
  • BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AzurRx or the Company) ( NASDAQ: AZRX ), a company specializing in the development of targeted non-systemic, therapies forgastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately.
  • Terry brings to AzurRx unrivaled financial and operational experience, which will be critical to our growth and long-term success.
  • On behalf of the Board, I am pleased to welcome Terry to AzurRx and look forward to benefitting from her knowledge and expertise.
  • I am honored to be joining the Board of AzurRx BioPharma, said Ms. Coelho.